At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 44 enrolled
Drug / intervention
Odanacatib +1 moredrug
Likely dose
Odanacatib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Odanacatib (MK0822) in Healthy Male and Postmenopausal Female Subjects
In Brief
A Phase 1 clinical trial evaluating Odanacatib and Comparator: Placebo for Osteoporosis. Completed, enrolled 44 participants.
Detailed Summary
This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2009
First PostedFeb 2010
Primary CompletionApr 2010
Study CompletionMay 2010
TodayJul 2026
First PostedFeb 12, 2010
Enrollment StartDec 8, 2009
Primary CompletionApr 26, 2010
Study CompletionMay 2, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.4 years ago
Interventions
Odanacatibdrug
Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks
Comparator: Placebodrug
Oral Placebo tablet administered once weekly for 4 consecutive weeks